Savulescu Warns that “Love-Diminishing” Drugs could be Used for Gay “Conversion Therapy”
By Xavier Symons,
BioEdge
| 10. 12. 2013
In recent years Oxford bioethicist Julian Savulescu has written extensively about the neuro-enhancement of human relationships. In a number of papers, he has studied the ethics of using drugs to strengthen or improve romantic relationships. But how about the use of “individual, voluntary use of love-diminishing biotechnology”? In other words, drugs which would inhibit or reduce love or sexual attraction. If love is essentially chemical, the tap can be turned on or off.
Although this is currently not feasible, Savulescu and co-authors Brian D. Earp and Anders Sandberg warn that drugs could be used to reverse homosexual inclinations. In a controversial paper in the
American Journal of Bioethics: Neuroscience, “
Brave new love: The threat of high-tech ‘conversion’ therapy and the bio-oppression of sexual minorities”, they examine the ethics of using drugs to “normalize” people with atypical sexual desires.
They conclude that the use of conversion drugs on minors should be illegal but “in rare cases” they could be used by consenting adults, even if they are religious fundamentalists. “It seems hard to maintain… that John Stuart Mill’s...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Peter Wehling, Tino Plümecke, and Isabelle Bartram
| 03.26.2025
This article was originally published as “Soziogenomik und polygene Scores” in issue 272 (February 2025) of the German-language journal Gen-ethischer Informationsdienst (GID); translated by the authors.
In mid-November 2024, the British organization Hope not Hate published its investigative research ‘Inside the Eugenics Revival’. In addition to documentating an active international “race research” network, the investigation also brought to light the existence of a US start-up that offers eugenic embryo selection. Heliospect Genomics aims to enable wealthy couples to...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...